Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Conditions
Brief summary
This phase II trial studies the use of 68Ga-PSMA-11 positron emission tomography (PET) in diagnosing patients with prostate cancer that continues to grow despite the surgical removal of the testes or medical intervention to block androgen production (castration resistant), and has spread to other places in the body (metastatic). 68Ga- PSMA-11 is a new imaging agent that may help get more detailed pictures of the tumor. This trial aims to see whether using 68Ga-PSMA-11 PET scans may help doctors learn more about where disease is located in the body.
Detailed description
PRIMARY OBJECTIVE: I. To determine whether the percent change from baseline to 16 weeks (+/- 8 weeks) in maximum standard uptake value (SUVmax) averaged across up to 16 lesions per patient (SUVmax-ave) is associated with \>= 50% decline from baseline in serum prostate specific antigen (PSA50) response. SECONDARY OBJECTIVES: I. To determine whether the percent change from baseline in SUVmax-ave on PSMA PET is associated with time-to-event endpoints including PSA progression-free survival and overall survival. II. To determine whether the percent change from baseline in SUVmax on PSMA PET is associated with objective response by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 on a per-lesion basis among measurable soft tissue lesions present at baseline. EXPLORATORY (CORRELATIVE) OBJECTIVES: I. To descriptively characterize the histologic, transcriptional, and genomic features of PSMA low/negative lesions among patients who undergo paired optional metastatic tumor biopsy. II. To descriptively characterize the relationship between SUVmax-ave on baseline Ga-PSMA PET with optional baseline fludeoxyglucose F-18 (FDG)-PET. III. To determine whether heterogeneity of PSMA expression on baseline Ga-PSMA PET is associated with overall survival. IV. To descriptively characterize the patterns of PSMA expression at the time of disease progression among patients who undergo optional PSMA PET. V. To determine whether the percent change from baseline in PSMA PET is associated with PSA50 response among subgroups of patients defined by treatment modality received, including androgen receptor (AR) targeting treatment, PSMA-targeting radioligand therapy, cytotoxic chemotherapy, and immunotherapy. OUTLINE: Patients receive gallium Ga 68-PSMA-11 intravenously (IV) and undergo PET at baseline, 16 weeks after initiating therapy, and at time of disease progression. After progression or study completion, patients are followed up every 3 months for up to 24 months
Interventions
DRUG68Ga-PSMA-11
Given IV
PROCEDUREPositron Emission Tomography (PET)
Undergo PET
Sponsors
Thomas Hope
Conquer Cancer Foundation
Gateway for Cancer Research
Prostate Cancer Foundation
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Sub-cohort A1: Patients must have baseline evaluations performed within 12 weeks prior to the start of systemic therapy. 2. Sub-cohort A2: Patients must meet all the following requirements: * Have had a baseline pre-treatment 68Ga-PSMA-11 PET scan and PSA measurement performed within 12 weeks prior to the start of current systemic therapy. * Able to have an on-treatment 68Ga-PSMA-11 PET and a PSA measurement within 16 weeks (+/- 8 weeks) after the start of current systemic therapy. Note: The screening period for sub-cohort A2 is within 24 weeks after the patient started their current systemic therapy. 3. Patients must have progressive castration resistant prostate cancer, according to PCWG3 criteria. 4. Patients must have planned initiation of systemic treatment (sub-cohort A1), or ongoing systemic treatment (sub-cohort A2) for castration resistant prostate cancer within 12 weeks of baseline Ga-PSMA PET. 5. Patients must have at least one metastatic lesion with PSMA uptake at or above the blood pool on their baseline PSMA PET scan. 6. The patient must be able and willing to comply with study procedures and provide signed and dated informed consent. 7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 8. Patient must be Aged 18 years or older at the time of study entry. 9. Patients who undergo optional metastatic tumor biopsy following completion of baseline Ga-PSMA PET must additionally meet all of the following criteria: * Presence of one or more metastases by standard radiographic scans that is safely accessible to tumor biopsy in the judgment of treating clinician and/or Interventional Radiology. * No history of radiation therapy to the target metastatic lesion selected for tumor biopsy. * No contra-indication to biopsy including uncontrolled bleeding diathesis. * Platelets \> 75,000/ul and prothrombin time (PT) or institution normalized ratio (INR) and a partial thromboplastin time (PTT) \< 1.5 times the institutional upper limit of normal (ULN) within 14 days prior to biopsy.
Exclusion criteria
1. Patients who because of age, general medical or psychiatric condition, or physiologic status cannot give valid informed consent. 2. Patients with any condition that, in the opinion of the Principal Investigator, would impair the patient's ability to comply with study procedures. 3. Patients with any contra-indication to magnetic resonance imaging (MRI) (e.g. pacemaker placement, severe claustrophobia) Note: The
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean Maximum Standard Uptake Value (SUVmax) | Baseline, and up to 16 weeks after initiation of therapy | The mean SUVmax and standard deviation across the primary tumor and the 5 largest lesions in each of three metastatic sites (nodal, visceral and osseous; for a maximum of 16 lesions per patient) will be descriptively reported. |
| Median SUVmax | Baseline, and up to 16 weeks after initiation of therapy | The median and range of SUVmax across the primary tumor and the 5 largest lesions in each of three metastatic sites (nodal, visceral and osseous; for a maximum of 16 lesions per patient) will be descriptively reported. |
| Percentage of Participants Who Progressed by Prostate-specific Antigen (PSA) Response Group | Baseline, and up to 16 weeks after initiation of therapy | The percent of participants who fall into the PSA50 responders vs. non-responders based on PSMA treatment response criteria (PPP) for progression status will be reported. PPP uses 3 different criteria to determine response: 1) Appearance of 2 or more new PSMA positive distant lesions, 2) Appearance of 1 new PSMA positive lesion plus consistent clinical and/or laboratory data and recommended confirmation by biopsy or correlative imaging within 3 months of PSMA PET, and 3) Increase in size or PSMA uptake of 1 or more existing lesions by 30% plus consistent clinical and/or laboratory data and/or confirmation by biopsy or correlative imaging within 3 months of PSMA PET. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) by PET Response Group | Up to 48 months | The study cohort will be dichotomized by participants who fall into the responders vs. non-responders (progressed vs not progressed) based on PSMA PET response criteria (PPP) for progression status will be reported. PPP uses 3 different criteria to determine response: 1) Appearance of 2 or more new PSMA positive distant lesions, 2) Appearance of 1 new PSMA positive lesion plus consistent clinical and/or laboratory data and recommended confirmation by biopsy or correlative imaging within 3 months of PSMA PET, and 3) Increase in size or PSMA uptake of 1 or more existing lesions by 30% plus consistent clinical and/or laboratory data and/or confirmation by biopsy or correlative imaging within 3 months of PSMA PET. PSA progression-free will be defined by Prostate Cancer Clinical Trials Working Group 3 (PCWG3). The median PFS in months with 95% confidence interval will be reported. |
| Objective Response by PET Response Group | Baseline, and up to 16 weeks after initiation of therapy | The study cohort will be dichotomized by participants who fall into the responders vs. non-responders (progressed vs not progressed) based on PSMA PET response criteria (PPP) for progression status will be reported. PPP uses 3 different criteria to determine response: 1) Appearance of 2 or more new PSMA positive distant lesions, 2) Appearance of 1 new PSMA positive lesion plus consistent clinical and/or laboratory data and recommended confirmation by biopsy or correlative imaging within 3 months of PSMA PET, and 3) Increase in size or PSMA uptake of 1 or more existing lesions by 30% plus consistent clinical and/or laboratory data and/or confirmation by biopsy or correlative imaging within 3 months of PSMA PET. PSA progression-free will be defined by Prostate Cancer Clinical Trials Working Group 3 (PCWG3). The percentage of participants who obtained an objective response per Response Evaluation Criteria in Solid Tumors (RECIST) will be reported. |
| Overall Survival (OS) by PET Response Group | Up to 48 months | The study cohort will be dichotomized by participants who fall into the responders vs. non-responders (progressed vs not progressed) based on PSMA PET response criteria (PPP) for progression status will be reported. PPP uses 3 different criteria to determine response: 1) Appearance of 2 or more new PSMA positive distant lesions, 2) Appearance of 1 new PSMA positive lesion plus consistent clinical and/or laboratory data and recommended confirmation by biopsy or correlative imaging within 3 months of PSMA PET, and 3) Increase in size or PSMA uptake of 1 or more existing lesions by 30% plus consistent clinical and/or laboratory data and/or confirmation by biopsy or correlative imaging within 3 months of PSMA PET. PSA progression-free will be defined by Prostate Cancer Clinical Trials Working Group 3 (PCWG3). The median OS and 95% confidence interval will be reported. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORIvan A de Kouchovsky, MD
University of California, San Francisco
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Experimental (68Ga-PSMA-11 PET) Patients receive gallium 68Ga-PSMA-11 IV and undergo PET at baseline, 16 weeks after initiating therapy, and at time of disease progression. | 15 |
| Total | 15 |
Baseline characteristics
| Characteristic | Experimental (68Ga-PSMA-11 PET) |
|---|---|
| Age, Customized 40-49 years old | 1 Participants |
| Age, Customized 50-59 years old | 2 Participants |
| Age, Customized 60-69 years old | 2 Participants |
| Age, Customized 70-79 years old | 8 Participants |
| Age, Customized 80-89 years old | 2 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 15 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 3 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 12 Participants |
| Region of Enrollment United States | 15 participants |
| Sex: Female, Male Female | 0 Participants |
| Sex: Female, Male Male | 15 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 3 / 15 |
| other Total, other adverse events | 0 / 15 |
| serious Total, serious adverse events | 0 / 15 |
Outcome results
Primary
Mean Maximum Standard Uptake Value (SUVmax)
The mean SUVmax and standard deviation across the primary tumor and the 5 largest lesions in each of three metastatic sites (nodal, visceral and osseous; for a maximum of 16 lesions per patient) will be descriptively reported.
Time frame: Baseline, and up to 16 weeks after initiation of therapy
Population: Data not collected
Primary
Median SUVmax
The median and range of SUVmax across the primary tumor and the 5 largest lesions in each of three metastatic sites (nodal, visceral and osseous; for a maximum of 16 lesions per patient) will be descriptively reported.
Time frame: Baseline, and up to 16 weeks after initiation of therapy
Population: Data not collected
Primary
Percentage of Participants Who Progressed by Prostate-specific Antigen (PSA) Response Group
The percent of participants who fall into the PSA50 responders vs. non-responders based on PSMA treatment response criteria (PPP) for progression status will be reported. PPP uses 3 different criteria to determine response: 1) Appearance of 2 or more new PSMA positive distant lesions, 2) Appearance of 1 new PSMA positive lesion plus consistent clinical and/or laboratory data and recommended confirmation by biopsy or correlative imaging within 3 months of PSMA PET, and 3) Increase in size or PSMA uptake of 1 or more existing lesions by 30% plus consistent clinical and/or laboratory data and/or confirmation by biopsy or correlative imaging within 3 months of PSMA PET.
Time frame: Baseline, and up to 16 weeks after initiation of therapy
Population: Participants were divided into subgroups based on whether or not the participant experienced a \>= 50% decline from baseline in serum PSA
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Experimental (68Ga-PSMA-11 PET) | Percentage of Participants Who Progressed by Prostate-specific Antigen (PSA) Response Group | PSA Responders who progressed | 11.1 percentage of participants by group |
| Experimental (68Ga-PSMA-11 PET) | Percentage of Participants Who Progressed by Prostate-specific Antigen (PSA) Response Group | PSA Non-Responders who progressed | 83.3 percentage of participants by group |
Secondary
Comparison Between Mean Percent Change in SUVmax With Objective Response Group
Amongst the subset of measurable soft tissue lesions by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, on a per-lesion basis, the mean percent change from baseline in SUVmax on PSMA PET will be compared between responding lesions defined as a complete response or partial response by RECIST 1.1 criteria vs. those without response, using Mann-Whitney test.
Time frame: Baseline, and up to 16 weeks after initiation of therapy
Secondary
Comparison of Change in SUVmax-ave Group on Overall Survival (OS)
The study cohort will be dichotomized by the median with respect to percent change from baseline in SUVmax-ave on PSMA PET on overall survival defined as time from imaging until death or censored at study completion. OS will be compared between dichotomized subgroups using the log-rank test. Kaplan-Meier product limit method will be used to estimate median survival in each subgroup.
Time frame: Up to 24 months
Secondary
Comparison of Change in SUVmax-ave Group on Progression Free Survival (PFS)
The study cohort will be dichotomized by the median with respect to percent change from baseline in SUVmax-ave on PSMA PET. The time-to-event variables including PSA progression-free will be defined by Prostate Cancer Clinical Trials Working Group 3 (PCWG3).
Time frame: Up to 24 months